Dr. Frenkl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Civic Center Blvd
West Pavilion, 3rd Floor
Philadelphia, PA 19104Phone+1 215-662-2891Fax+1 215-662-6734- Is this information wrong?
Education & Training
- Brown UniversityResidency, Urology, 1999 - 2003
- Brown UniversityResidency, Surgery, 1998 - 1999
- Duke University HospitalInternship, Transitional Year, 1996 - 1997
- Rutgers Robert Wood Johnson Medical SchoolClass of 1996
Certifications & Licensure
- PA State Medical License 2006 - 2024
- OH State Medical License 2003 - 2007
- NJ State Medical License 1992 - 2007
- NC State Medical License 1997 - 1998
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 187 citationsPembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, ...Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, Mathieu Roumiguié, Laurence Eliot Miles Krieger, Eric A. Singer, Dean F. Bajo...> ;The Lancet. Oncology. 2021 Jul 1
- 136 citationsLong-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Sava...> ;Journal of Clinical Oncology. 2020 Jun 17
- 13 citationsThe cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United StatesRachael Louise Slater, Yizhen Lai, Yichen Zhong, Haojie Li, Yang Meng, Blanca Homet Moreno, James Luke Godwin, Tara L. Frenkl, Guru Sonpavde, Ronac Mamtani> ;Journal of Medical Economics. 2020 Jun 12
- Join now to see all
Press Mentions
- Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
- Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
- Bayer : New Data Presented at ASCO GU Confirm Survival Benefits and Favorable Safety Profile of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate CancerFebruary 20th, 2023
Hospital Affiliations
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: